Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05501756 · ClinicalTrials.gov registry record · Phase 2
Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
A Phase 2 study of Allogeneic Hematopoietic Cell Transplantation, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05501756: Recruiting Phase 2 study of Allogeneic Hematopoietic Cell Transplantation, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT05501756 is a Phase 2 study of Allogeneic Hematopoietic Cell Transplantation that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05501756, a Phase 2 study of Allogeneic Hematopoietic Cell Transplantation, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Alemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT). In this research study the investigators want to find out if they can adjust the dose of alemtuzumab used as part of allogeneic HCT to target the level of Day 0 (the planned day of graft infusion) to an optimal therapeutic window of 0.15-0.9 ug/mL.
Primary Outcome
Number of patients who have alemtuzumab levels in the optimal therapeutic range on Day 0.
Conditions Studied
Interventions
- DRUG Alemtuzumab
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-01-11 |
| Est. Completion | 2028-08-31 |
| Phase | Phase 2 |
What NCT05501756 shows while recruiting
NCT05501756 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Allogeneic Hematopoietic Cell Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Alemtuzumab is the first listed.
NCT05501756 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05501756 about?
NCT05501756 is a clinical study titled "Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation". Alemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT). In this research study the investigators want to find out if they can adjust the dose of alemtuzumab used as part of allogeneic HCT to target the...
What is the current status of trial NCT05501756?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-01-11. Estimated completion is 2028-08-31.
What conditions does trial NCT05501756 study?
This clinical trial studies the following conditions: Allogeneic Hematopoietic Cell Transplantation.
What interventions are being tested in trial NCT05501756?
The interventions under investigation include: Alemtuzumab (DRUG).
Who is sponsoring clinical trial NCT05501756?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05501756 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allogeneic Hematopoietic Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05501756's enrollment target sits among peer trials
60 1027th of 2000 higher than 869 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI